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Abstract. Malaria, an infectious disease causes by Plasmodium, contribute to 300-900 million morbidities and 1-3 million 
mortalities, annually. This study aimed to determine the Rubella vaccine potency to inhibit Plasmodium berghei merozoite 
invasion to erythrocyte which evaluated from parasitemia levels, mortality and mice clinical condition. This study 
conducted in mice injected Rubella vaccine prior injected with P. berghei. There were four groups: A, B and C injected 
with 500 µl, 2 µl, and 1 µl rubella vaccine respectively. Group D injected with 500 µl sterile aqua, as control group. After 
28 days of vaccination all mice injected with 0.2 ml P. berghei. Furthermore, we observed to parasitemia levels, death, 
and clinical condition of mice to assess Rubella vaccine effectiveness to inhibit merozoite invasion. The results shown 
Rubella vaccine did not provide significant effect on parasitemia levels. It might Rubella vaccine dose we used under 
effective dose and less effective of target site. However, our study shown Rubella vaccine provided significant effect on 
mice mortality (p<0.05). It is probably due to Rubella antigen (213-239 amino acid sequence) and malaria antigen 
merozoite surface protein (MSP)-119 (sequence amino acid 238) has similar structure, thus it was likely generated cross-
immunity. In conclusion, 28 days Rubella vaccination did not provide significant effect on parasitemia levels, however it 
provided significant effect on mice mortality with infected by P. berghei. 
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Introduction 
Malaria, an infectious disease causes by Plasmodium, causes 300-900 million morbidities 
and 1-3 million mortalities annually (WHO, 2005). Effective malaria vaccine to reduce malaria 
incidence is still unavailable. Recently, malaria vaccine, SPF-66, was proved to be efficacious 
because it did not increase natural antibody to malaria and decrease interferon (IFN)-γ levels, 
thus SPF-66 seem uncorrelated with protection against malaria (Wang et al., 2010). It was 
allegedly because SPF-66 has ineffective target sites.  There are three sporozoite surface 
proteins, 83, 55, and 35 kDa (Graves & Gelband, 2009). Therefore, it is necessary to find out 
new alternative vaccine which has a potential target site to increase immunity against malaria. 
Previous study showed that merozoite surface protein (MSP)-119 was potential target for malaria 
vaccine, because MSP-119 has essential role in merozoite expansion to erythrocyte (Dluwzeski et 
al., 2008). MSP-119 has two epidermal growth factors (EGFs). MSP-119 has an N-glycosylation 
area on the overall length of MSP-1 and MSP-119 that may come through N-glycosylation when 
expressed in mammalian cells (Langhorne, 2005). Study by Li et al. (2008) shown MSP-119 
antigen is a peptide protein antigen which has 238 amino acid sequences.  Rubella proteins have 
three structures, envelop 1 (E1), envelop 2 (E2), and capsid (C). E1 and E2, membrane 
glycoproteins, are part of the rubella virus that consist cysteine-rich glycoprotein (Abernathy et 
al., 2009). The role of these proteins is associated with membrane fusion process (Liu et al., 
2009; Zhou et al., 2009).   
Several studies confirmed E1 is a peptide protein antigen which has 213-239 amino acid 
sequences (Mitchell et al., 1994; Ovsyannikova et al., 2004; Ovsyannikova et al., 2006). Based 
on amino acid sequence similarity between E1 Rubella and MSP-119 Plasmodium, we predicted 
that there was host cross-immune development which protect host against Plasmodium if we 
treat with Rubella vaccine prior infect with Plasmodium parasite. Therefore, present study to 
determine Rubella vaccine potency to inhibit Plasmodium berghei merozoite invasion to 
erythrocytes which evaluated from parasitemia levels, mortality and mice clinical condition.  
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Materials and Methods 
Research design 
Post test-only control group design was used in this study. Mice divided in 4 groups (A, B, 
C and D), and each group consist 5 mice. Group A, B and C injected with 500 µl, 2 µl, and 1 µl 
Rubella vaccine per subcutaneously respectively. Group D injected with 500 µl sterile aqua, as 
control group. After 28 days of vaccination all mice injected with 0.2 ml P. berghei.  
Rubella vaccine preparation 
Rubella vaccine used was mmr II, purchased from Kimia Farma, Surabaya, Indonesia. 
Rubella vaccine dose preparation, 500µl, 1µl and 2µl based on manufacture instruction.   
P. berghei preparation 
P. berghei preparation was conducted at Parasitology and Biomedical Laboratory, School 
of Medicine Brawijaya University, Malang, using standard procedures of P. berghei thawing 
process which described previously (Doolan, 2002).   
Microscopic examination   
Malaria microscopic preparation and parasitemia level determination carried out according 
to standard procedures (Doolan, 2002). Briefly, parasitemia levels are accessed on 5th day after 
P. berghei infection; we counted the number of Plasmodium-infected leukocyte per 200 
leukocytes or per 1000 erythrocytes.  
Statistical analysis 
Statistical analysis in this study was ANOVA one way using Statistics Calculators version 
2.0 with p<0.05. 
 
Results and Discussion 
The results of parasitemia can be seen in Fig. 1A-C, while the results the mice mortality 
can be seen in Fig. 1D. Furthermore, these parasitemia datas used to calculate malaria invasion 
inhibition. Fig. 1A-C showed that group A had the lowest average parasitemia and had the 
highest inhibition value. Data analysis on parasitemia level and parasite number per µl of blood 
found there were no statistically significant, p=0.2, p=0.09 respectively.  In term of mice 
mortality (See Fig. 1D). Group A had the lowest number of mice mortality. In addition, group A 
also showed a good clinical condition. The result of variance analysis of the mice mortality 
obtained F-value of the 6th day of death was 1.333 [F table 3.24] and F-value of overall mortality 
was 5.867 [F table 3.24]. It indicated that Rubella vaccine effected mice infected P. berghei 
mortality significantly (p<0.05).  
Parasitemia, parasite quantities in blood, is indicator to determine malaria growth or 
inhibition (Bisoffi et al., 2010). Based on parasitemia levels in this study we found there was no 
significant difference among groups. It might caused by Rubella vaccine doses used and Rubella 
vaccine target site effectiveness. The highest Rubella vaccine dose, 500 µl, inhibited 49% of 
parasitemia level. To obtain a higher inhibition effect may need to give a higher dose. However, 
Rubella vaccine toxicity at higher dose needs to be considered.  
Theoretically, target site of Rubella vaccine in this study was MSP-119. Merozoite invasion 
to erythrocyte is a complex process. It involves several merozoite surface proteins MSP such as 
erythrocyte binding protein (EBP), MSP-119, MSP-7, apical membrane antigen (AMA), acid basic 
repeat antigen (ABRA), and serine-repeat antigen (SERA) (Rollinson et al., 2009). Inhibition to 
MSP-119 indicates partial inhibition only to merozoite invasion to erythrocyte. Thus, this seems 
lead less effective inhibition. 
Based on data analysis shown Rubella vaccine effected on total mice mortality 
significantly (p<0.05). However, Rubella vaccine not significantly affected parasitemia levels and 
number of parasites, p=0.2 and p=0.09 respectively. The result showed group A has lowest in 
term of parasitemia levels, parasite number per µl of blood, and the number of deaths. Dose of 
group A was based on the product information whereas the dose of group B and C were based on 
weight conversion. Based on the results of this study indicated that the effectiveness of the best 
protection in this study was in group A. This protection had a 49% growth inhibition or the 
highest than other groups.  
Rubella vaccine protection against malaria might caused by amino acid sequence 
similarity between E1 Rubella virus and MSP-119 Plasmodium. E1 has 213-239 amino acid 
sequences and MSP-119 has 238 amino acid sequences (Prendergast & Mann, 1978; Mitchell et 
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al., 1996). Because of these structural similarities (between 5 or 10 amino acid sequences), it 
was predicted to lead specific immunity (Frank, 2002). The possibility pathway it can cause cross 
immunity reaction by inhibiting MSP-119. This immunity mechanism possibility involves human 
leukocyte antigen (HLA), IFN-γ, interleukin (IL)-10 and immunoglobulin (Ig)-G (Ovsyannikova et 
al., 2007; Aschermann et al., 2010). Furthermore this mechanism result inhibition mechanism 
and phagocytosis, caused a lower parasitemia level and mortality rate in group A. 
 
Figure 1. A. Total parasitemia percentage on 5th day after P. berghei infection. B. Average of parasitaemia percentage 
(group A=4,62%; group B= 5,82%; group C=7,58%; and group D=9%) and percentage of Rubella vaccine inhibition 
(group A=49%; group B=35%; and group C=16%). C. The number of parasites per µl of blood. The average of group 
A=10477; group B=19559; group C=14528; and group D=24701. D. Mice mortality after infected with P. berghei (total 
mortality of group A=1; group B=3; group C=5; and group D=5). 
 
Parasitemia level has a clear correlation with clinical condition and mortality rate (Doolan, 
2002). Merozoite invasion into erythrocyte is responsible to malaria clinical manifestations. This 
study shown good clinical conditions in group A, contrary in group B, C, and D which shown poor 
clinical conditions. Therefore, these results are consistent with another study confirmed that 
some virus vaccines could prevent malaria mortality (Hutchings et al., 2007). But advance 
research that to confirm the role of Rubella vaccine inhibition against malaria is need. 
 
Conclusions 
This study indicated that rubella vaccination did not provide significant effect on total 
parasitemia level of mice infected P. berghei. However, rubella vaccination provided significant 
effect on P. berghei infected-mice mortality (p<0.05) and it seem dose-dependent effect. 
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